Isabella Ciccone, Associate Editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter @iciccone7 or email her at iciccone@mjhlifesciences.com
Using SEEG Data to Decode Brain Activity for Decision-Making: Alexander C. Whiting, MD
December 13th 2024The director of epilepsy surgery at Allegheny Health Network talked about recent advances in brain signal analysis with stereoelectroencephalography and its potential for transforming care for decision-making disorders. [WATCH TIME: 4 minutes]
Honoring the Impact of Recognition and Advocacy in MS Care: Aprile Royal, RN, BA, MEd
December 11th 2024The manager of the BARLO MS education program at St. Michael's Hospital highlighted the significance of recognition, the pivotal role of nurses in multiple sclerosis care, and the lasting impact of mentorship and advocacy. [WATCH TIME: 5 minutes]
NeuroVoices: Alexander C. Whiting, MD, on Advancing Epilepsy Surgery and Brain Function Research
December 11th 2024The director of epilepsy surgery at Allegheny Health Network discussed how clinicians can successfully pinpoint the source of epilepsy in the brain through innovative procedures like stereo electroencephalography.
Understanding Clinical Predictors of Response to Nabilone in Alzheimer Agitation
December 10th 2024Krista L. Lanctôt, PhD, professor of psychiatry and pharmacology at the University of Toronto, talked about findings from a recent post hoc analysis presented at CTAD 2024 on nabilone for agitation in Alzheimer disease.
Advancing Epilepsy Treatment and Brain Research Through SEEG: Alexander C. Whiting, MD
December 7th 2024The director of epilepsy surgery at Allegheny Health Network talked about research recently presented at AES 2024 on stereo-electroencephalography, a minimally invasive treatment for patients with epilepsy. [WATCH TIME: 7 minutes]
Interim Analysis Highlights Long-Term Safety of Azetukalner for Focal Epilepsy
December 6th 2024In a further date from the ongoing open-label extension of the phase 2b X-TOLE study, results demonstrated that the majority of treatment-emergent adverse events associated with azetukalner were mild or moderate.
FDA Grants NS-050/NCNP-03 Rare Pediatric Disease Designation in Duchenne Muscular Dystrophy
December 5th 2024A recently initiated phase 1/2 trial of NS-050/NCNP-03 will assess patients with Duchenne muscular dystrophy on dystrophin production, muscle strength, mobility, and functional exercise capacity.
Higher Dose of Nusinersen Shows Greater Impact on Spinal Muscular Atrophy in Phase 2/3 DEVOTE Study
December 1st 2024Findings from a phase 2/3 study demonstrated the efficacy and safety of a higher dose regimen of nusinersen in treating spinal muscular atrophy in both treatment-naïve and previously treated patients.
Prevalence, Diagnosis, and Treatment Approaches for Restless Legs Syndrome
November 29th 2024Shalini Paruthi, MD, FAASM, a spokesperson for the American Academy of Sleep Medicine, provided a clinical overview on restless leg syndrome for diagnosing and tailoring treatment for patients with the condition.
Race, Socioeconomic Status Play Major Role in Disparities Seen in Pediatric NMOSD Outcomes
Published: November 27th 2024 | Updated: December 11th 2024A new study revealed stark racial and socioeconomic disparities in pediatric neuromyelitis optica spectrum disorder outcomes, underscoring the need for targeted interventions.
Redesigning Clinical Trials in Alzheimer Disease to Promote Diversity and Accessibility
November 23rd 2024Jessica Langbaum, PhD, the senior director of research strategy at Banner Alzheimer’s Institute, discussed the challenges and opportunities in improving diversity in Alzheimer disease clinical trials.
Coupling Eye Movements and Postural Sway Significantly Enhances Stability in Parkinson Disease
November 22nd 2024Findings from a recently published study suggest patients with Parkinson disease can reduce postural sway as efficiently as neurologically healthy patients when performing horizontal saccades.
Exploring Blood-Based Biomarkers and Treatment Eligibility in Alzheimer Disease: Gil Rabinovici, MD
November 21st 2024The professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes]
Highlights on Exploring Advances in Headache Medicine from AHS Scottsdale 2024: MaryAnn Mays, MD
November 21st 2024The neurologist in the Headache Center at Cleveland Clinic shared her post perspective on the 2024 AHS Scottsdale meeting which highlighted advancements in headache medicine and the growing impact of the field on patient care. [WATCH TIME: 5 minutes]